IGC PharmaIGC +1.83%29 EBITDA Margin % is -757.10% as of Mar. 2026. GuruFocus rates IGC with a GF Score™ of 29/100 and a GF Value™ of $0.24 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 944 Biotechnology companies, IGC Pharma ranks worse than 77.86% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. IGC Pharma's EBITDA for the
three
months ended in Mar. 2026 was $-2.40 Mil. IGC Pharma's Revenue for the
three
months ended in Mar. 2026 was $0.32 Mil. Therefore, IGC Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was -757.10%.
IGC Pharma (AMEX:IGC) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
IGC Pharma EBITDA Margin % Related Terms
IGC Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for IGC Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC vs CRVO, NEUP, CELU: EBITDA Margin % Comparison
For the Biotechnology subindustry, IGC Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where IGC Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma (IGC) has a EBITDA Margin % of -757.10% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IGC Pharma and its competitors. According to the industry distribution chart, IGC Pharma ranks #735 out of 944 companies in the Biotechnology industry, placing it in the top 77.9%.
Is IGC Pharma's EBITDA Margin % too high?
IGC Pharma's current EBITDA Margin % is -757.10%. Based on the distribution chart, IGC Pharma ranks #735 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, IGC Pharma has a GF Score™ of 29/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's EBITDA Margin % compare to CRVO and NEUP?
According to the Biotechnology industry distribution chart, IGC Pharma ranks #735 out of 944 companies for EBITDA Margin %. This places IGC Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IGC Pharma and its competitors. IGC Pharma's current EBITDA Margin % is -757.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.27 — trading 11.1% above its estimated fair value. The current EBITDA Margin % is -757.10%. IGC Pharma's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For IGC Pharma (IGC), the current EBITDA Margin % is -757.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IGC Pharma (IGC) Overvalued in 2026?
Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued.
The current stock price of $0.27 is trading 11.1% above its estimated GF Value™ of $0.24.
GuruFocus considers IGC Pharma to be Modestly Overvalued.
Key valuation signals for IGC:
EBITDA Margin %: -757.10%
GF Value™: $0.24 vs. price of $0.27 (11.1% above fair value)
No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score
Get the complete analysis for IGC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IGC has been successfully added to your 
